Anti-MUC1 CAR-pNK cells- PersonGen BiomedicineAlternative Names: Anti-MUC1 chimeric antigen receptor natural killer cells - PersonGen Biomedicine; Anti-mucin1 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine
Latest Information Update: 28 Jul 2016
At a glance
- Originator PersonGen Biomedicine
- Class Antineoplastics; Cell therapies; Gene therapies
- Mechanism of Action Gene transference; Mucin 1 inhibitors; Natural killer cell receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Jul 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (Parenteral) (NCT02839954)